RASJ
MCID: RHM021
MIFTS: 59

Rheumatoid Arthritis, Systemic Juvenile (RASJ) malady

Categories: Genetic diseases, Rare diseases, Respiratory diseases, Bone diseases

Aliases & Classifications for Rheumatoid Arthritis, Systemic Juvenile

Aliases & Descriptions for Rheumatoid Arthritis, Systemic Juvenile:

Name: Rheumatoid Arthritis, Systemic Juvenile 54 52 69
Juvenile Rheumatoid Arthritis 12 50 25 14 69
Juvenile Idiopathic Arthritis 12 50 25 14
Juvenile Arthritis 50 41 69
Monarticular Juvenile Rheumatoid Arthritis 12 69
Systemic Juvenile Rheumatoid Arthritis 12 25
Rheumatoid Arthritis Systemic Juvenile 66 29
Juvenile Chronic Polyarthritis 12 69
Arthritis, Juvenile Rheumatoid 50 25
Juvenile-Onset Still Disease 66 69
Juvenile Chronic Arthritis 50 25
Rheumatoid Arthritis, Systemic Juvenile, Susceptibility to 13
Acute Polyarticular Juvenile Rheumatoid Arthritis 69
Pauciarticular Onset Juvenile Chronic Arthritis 12
Systemic-Onset Juvenile Idiopathic Arthritis 56
Pauciarticular Juvenile Rheumatoid Arthritis 69
Systemic Onset Juvenile Chronic Arthritis 69
Acute Juvenile Rheumatoid Arthritis 12
Pauciarticular Juvenile Arthritis 12
Arthritis Juvenile Rheumatoid 52
Systemic Polyarthritis 56
Arthritis, Juvenile 42
Systemic-Onset Jia 56
Stills Disease 52
Still Disease 56
Juvenile Ra 25
Rasj 66
Jia 25
Jra 25

Characteristics:

Orphanet epidemiological data:

56
systemic-onset juvenile idiopathic arthritis
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Europe); Age of onset: Childhood; Age of death: normal life expectancy;

Classifications:



Summaries for Rheumatoid Arthritis, Systemic Juvenile

MedlinePlus : 41 juvenile arthritis (ja) is arthritis that happens in children. it causes joint swelling, pain, stiffness, and loss of motion. it can affect any joint, but is more common in the knees, hands, and feet. in some cases it can affect internal organs as well. the most common type of ja that children get is juvenile idiopathic arthritis. there are several other forms of arthritis affecting children. one early sign of ja may be limping in the morning. symptoms can come and go. some children have just one or two flare-ups. others have symptoms that never go away. ja can cause growth problems and eye inflammation in some children. no one knows exactly what causes ja. most types are autoimmune disorders. this means that your immune system, which normally helps your body fight infection, attacks your body's own tissues. ja can be hard to diagnose. your health care provider may do a physical exam, lab tests, and x-rays. a team of providers usually treats ja. medicines and physical therapy can help maintain movement and reduce swelling and pain. they may also help prevent and treat complications. nih: national institute of arthritis and musculoskeletal and skin diseases

MalaCards based summary : Rheumatoid Arthritis, Systemic Juvenile, also known as juvenile rheumatoid arthritis, is related to rheumatoid arthritis and hepatitis, and has symptoms including arthralgia, fever and abdominal pain. An important gene associated with Rheumatoid Arthritis, Systemic Juvenile is IL6 (Interleukin 6), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Leflunomide and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and eye, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A rheumatoid arthritis that involves an autoimmune disease onset in children under 16 which attacks the healthy cells and tissue of located in joint.

Genetics Home Reference : 25 Juvenile idiopathic arthritis refers to a group of conditions involving joint inflammation (arthritis) that first appears before the age of 16. This condition is an autoimmune disorder, which means that the immune system malfunctions and attacks the body's organs and tissues, in this case the joints.

NIH Rare Diseases : 50 juvenile idiopathic arthritis is an autoimmune condition that causes pain and swelling in a child's joints. when the immune system attacks the tissues of the joints, the resulting inflammation can cause joint damage, resulting in the pain and swelling characteristic of the disease. some children who have juvenile idiopathic arthritis are affected by episodes where the symptoms worsen, called flares. like most other autoimmune conditions, juvenile idiopathic arthritis is caused by a combination of genetic and environmental factors. to be diagnosed with juvenile idiopathic arthritis, the symptoms must have begun before age 16. diagnosis of the condition may be based on blood tests, x-rays, and ruling out other similar conditions. treatment options may include medications and  physical therapy. last updated: 1/11/2017

UniProtKB/Swiss-Prot : 66 Rheumatoid arthritis systemic juvenile: An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.

Wikipedia : 71 Juvenile idiopathic arthritis (JIA), also known as juvenile rheumatoid arthritis, is the most common... more...

Description from OMIM: 604302

Related Diseases for Rheumatoid Arthritis, Systemic Juvenile

Diseases in the Rheumatoid Arthritis family:

Rheumatoid Arthritis, Systemic Juvenile

Diseases related to Rheumatoid Arthritis, Systemic Juvenile via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 269)
id Related Disease Score Top Affiliating Genes
1 rheumatoid arthritis 30.9 BGLAP CRP HLA-DPB1 HLA-DQA1 HLA-DRB1 HSPD1
2 hepatitis 30.3 HLA-DRB1 IL6 TNF
3 joint disorders 30.1 CRP IL6 TNF
4 pulmonary hemosiderosis 30.0 HLA-DRB1 LTA TNF
5 celiac disease 29.8 BGLAP CRP IL1RN MRAP TNF TNFRSF1B
6 psoriatic juvenile idiopathic arthritis 12.5
7 enthesitis-related juvenile idiopathic arthritis 12.3
8 polyarticular onset juvenile idiopathic arthritis 11.2
9 multicentric carpotarsal osteolysis syndrome 11.2
10 arthropathy, progressive pseudorheumatoid, of childhood 11.2
11 systemic onset juvenile idiopathic arthritis 11.1
12 rheumatoid factor-negative juvenile idiopathic arthritis 11.1
13 arthritis 11.0
14 adult-onset still's disease 11.0
15 unilateral multicystic dysplastic kidney 10.4 CRP IL6 TNF
16 angiomatosis, diffuse corticomeningeal, of divry and van bogaert 10.4 HLA-DRB1 IL6 TNF
17 clostridium difficile colitis 10.4 HLA-DRB1 IL6 TNF
18 right ventricle hypoplasia 10.4 HLA-DRB1 MIF TNF
19 distal trisomy 14q 10.4 HLA-DPB1 HLA-DRB1 TNF
20 shoulder impingement syndrome 10.4 CRP IL1RN IL6
21 cicatricial lagophthalmos 10.4 CRP IL6 TNF
22 mineral metabolism disease 10.4 IL6 MIF TNF
23 hereditary alpha tryptasemia syndrome 10.4 HLA-DRB1 IL6 TNF
24 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.4 IL6 TNF
25 nemaline myopathy 1, autosomal dominant or recessive 10.4 IL1RN TNF TNFRSF1B
26 dextrocardia 10.4 IL1RN IL6 TNF
27 thymic neuroendocrine carcinoma 10.4 IL6 LTA TNF
28 anal paget's disease 10.4 IL1A IL6 TNF
29 gastric dilatation 10.4 HLA-DPB1 IL6 TNF
30 drug dependence 10.4 IL6 LTA TNF
31 warthin tumor 10.4 IL1R1 IL1RN TNF
32 neuropathy 10.4 CRP IL6 TNF
33 autoimmune disease of central nervous system 10.4 CRP IL6 TNF
34 bile duct signet ring cell carcinoma 10.4 CRP IL1R1 TNF
35 gonococcal endophthalmia 10.4 IL1RN IL6 TNF
36 aortic coarctation 10.4 IL2RA IL6 TNF
37 disease of mental health 10.4 HLA-DRB1 IL6 TNF
38 steroid dehydrogenase deficiency dental anomalies 10.4 IL1A IL6 TNF
39 cardiac tuberculosis 10.4 CRP IL6 MRAP
40 mikulicz disease 10.4 IL1A IL6 TNF
41 occupational dermatitis 10.4 MRAP TNF TNFRSF1B
42 functional gastric disease 10.4 CRP IL1R1 TNF
43 transient tic disorder 10.4 IL6 SLC11A1 TNF
44 cyclosporiasis 10.4 IL2RA IL6 TNF
45 pancreas lymphoma 10.4 CRP IL6 TNF
46 leydig cell hypoplasia 10.4 IL1R1 IL6 TNF
47 migraine with aura 10.4 HLA-DQA1 IL6 TNF
48 senile reticular retinal degeneration 10.4 IL1R1 IL1RN TNF
49 atrophy of prostate 10.4 CRP IL6 TNF
50 niemann-pick disease 10.4 HLA-DPB1 HLA-DRB1 IL6

Graphical network of the top 20 diseases related to Rheumatoid Arthritis, Systemic Juvenile:



Diseases related to Rheumatoid Arthritis, Systemic Juvenile

Symptoms & Phenotypes for Rheumatoid Arthritis, Systemic Juvenile

Clinical features from OMIM:

604302

Human phenotypes related to Rheumatoid Arthritis, Systemic Juvenile:

56 32 (show all 29)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthralgia 56 32 Very frequent (99-80%) HP:0002829
2 fever 56 32 Very frequent (99-80%) HP:0001945
3 abdominal pain 56 32 Occasional (29-5%) HP:0002027
4 joint swelling 56 32 Very frequent (99-80%) HP:0001386
5 splenomegaly 56 32 Occasional (29-5%) HP:0001744
6 hepatomegaly 56 32 Occasional (29-5%) HP:0002240
7 autoimmunity 56 32 Very frequent (99-80%) HP:0002960
8 pericarditis 56 32 Occasional (29-5%) HP:0001701
9 skin rash 56 32 Very frequent (99-80%) HP:0000988
10 elevated c-reactive protein level 56 32 Very frequent (99-80%) HP:0011227
11 lymphadenopathy 56 32 Frequent (79-30%) HP:0002716
12 pleural effusion 56 32 Occasional (29-5%) HP:0002202
13 elevated erythrocyte sedimentation rate 56 32 Very frequent (99-80%) HP:0003565
14 juvenile rheumatoid arthritis 56 32 Very frequent (99-80%) HP:0005681
15 anterior uveitis 56 32 Occasional (29-5%) HP:0012122
16 joint stiffness 32 HP:0001387
17 joint dislocation 32 HP:0001373
18 arthritis 32 HP:0001369
19 malabsorption 32 HP:0002024
20 generalized hyperkeratosis 32 HP:0005595
21 abnormality of the pleura 32 HP:0002103
22 abnormality of the fingernails 32 HP:0001231
23 mediastinal lymphadenopathy 32 HP:0100721
24 nail pits 32 HP:0001803
25 uveitis 32 HP:0000554
26 cartilage destruction 32 HP:0100773
27 abnormality of the sacroiliac joint 32 HP:0100781
28 psoriasis 32 HP:0003765
29 pericardial effusion 32 HP:0001698

UMLS symptoms related to Rheumatoid Arthritis, Systemic Juvenile:


back pain, muscle cramp, sciatica

MGI Mouse Phenotypes related to Rheumatoid Arthritis, Systemic Juvenile:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.93 HLA-DQA1 IL1A IL1R1 IL1RN IL2RA IL6
2 immune system MP:0005387 9.77 CRP HLA-DQA1 IL1A IL1R1 IL1RN IL2RA
3 neoplasm MP:0002006 9.23 TNF TNFRSF1B DEK IL1A IL1R1 IL6

Drugs & Therapeutics for Rheumatoid Arthritis, Systemic Juvenile

Drugs for Rheumatoid Arthritis, Systemic Juvenile (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Leflunomide Approved, Investigational Phase 4,Phase 2 75706-12-6 3899
2
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
3
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2 185243-69-0
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
5
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
7
Celecoxib Approved, Investigational Phase 4,Phase 3 169590-42-5 2662
8
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 1 22204-53-1 1302 156391
9
Famotidine Approved Phase 4 76824-35-6 3325
10
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
11
Ibuprofen Approved Phase 4 15687-27-1 3672
12
Esomeprazole Approved, Investigational Phase 4,Phase 1 161796-78-7, 119141-88-7 4594 9579578
13
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
14
Sulfasalazine Approved Phase 4,Phase 3 599-79-1 5353980 5359476
15
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
16
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
18
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 54575, 6560146 143
19 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
22 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
23 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
25 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
28 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
29 Vaccines Phase 4,Phase 3
30 Antiemetics Phase 4
31 Antimetabolites Phase 4,Phase 3,Phase 2
32 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
33 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
34 Autonomic Agents Phase 4
35 Dermatologic Agents Phase 4,Phase 3,Phase 2
36 Folic Acid Antagonists Phase 4,Phase 3,Phase 2
37 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1
38 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
39 Hormones Phase 4,Phase 3,Phase 2,Phase 1
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
41 Methylprednisolone acetate Phase 4,Phase 3,Phase 2
42 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2
43 Neuroprotective Agents Phase 4
44 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
45 Prednisolone acetate Phase 4,Phase 3,Phase 2
46 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2
47 Prednisolone phosphate Phase 4,Phase 3,Phase 2
48 Protective Agents Phase 4,Phase 3
49 Vitamin B Complex Phase 4,Phase 3,Phase 2
50 Liver Extracts Phase 4,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 202)
id Name Status NCT ID Phase
1 Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4
2 Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis Unknown status NCT01287715 Phase 4
3 Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis Unknown status NCT00573651 Phase 4
4 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
5 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4
6 Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Completed NCT00731965 Phase 4
7 A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects Completed NCT00807846 Phase 4
8 Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis Completed NCT01563185 Phase 4
9 A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA) Completed NCT01544114 Phase 4
10 Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis Completed NCT00443430 Phase 4
11 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy Completed NCT02196480 Phase 4
12 Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA Completed NCT00792233 Phase 4
13 Study Evaluating the Tolerance and Safety of Enbrel (Etanercept) in Adults and Children Completed NCT00484809 Phase 4
14 Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain Completed NCT00195377 Phase 4
15 Adolescent Fibromyalgia Study Completed NCT01020474 Phase 4
16 A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab) Recruiting NCT01734382 Phase 4
17 Intranasal Dexmedetomidine Sedation During Intra-articular Joint Injections in Pediatric Population Recruiting NCT03069638 Phase 4
18 Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis Terminated NCT00637780 Phase 4
19 The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis Unknown status NCT00012506 Phase 3
20 BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis Completed NCT00095173 Phase 3
21 A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis Completed NCT00036374 Phase 3
22 Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA) Completed NCT00048542 Phase 3
23 Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA) Completed NCT00034853 Phase 3
24 A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis Completed NCT00988221 Phase 3
25 Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis Completed NCT00690573 Phase 3
26 Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use Completed NCT00775437 Phase 3
27 A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA) Completed NCT00642460 Phase 3
28 A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA) Completed NCT00279747 Phase 3
29 An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study Completed NCT01727986 Phase 3
30 Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis Completed NCT01015547 Phase 3
31 Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis Completed NCT01541917 Phase 3
32 Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS Completed NCT00339157 Phase 2, Phase 3
33 A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study Completed NCT01667471 Phase 3
34 A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study Completed NCT01673919 Phase 3
35 An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Wi Completed NCT00891046 Phase 3
36 Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis Completed NCT00420251 Phase 3
37 Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis Completed NCT01385826 Phase 2, Phase 3
38 Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) Completed NCT00889863 Phase 3
39 Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis Completed NCT00962741 Phase 3
40 Supplementation With Vitamin D, Calcium or Both on Calcium Absorption and Bone Mineral Content in Children With JRA Completed NCT00570934 Phase 3
41 Comparison of Two Different Methods of Delivering Local Analgesia During Intra-articular Corticosteroid Injections in Children With Juvenile Idiopathic Arthritis Completed NCT00465504 Phase 3
42 A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA Completed NCT00652925 Phase 3
43 Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) Completed NCT00144599 Phase 3
44 Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA) Completed NCT00144664 Phase 3
45 Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) Completed NCT00144612 Phase 3
46 Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA) Completed NCT00144625 Phase 3
47 Alendronate Osteoporosis Study Completed NCT00277251 Phase 2, Phase 3
48 Efficacy Study of Recombinant Growth Hormone on Muscle Function in Children Long-term Treated With Glucocorticoid Completed NCT00813189 Phase 3
49 Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg) Completed NCT00001768 Phase 3
50 A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis Completed NCT01166282 Phase 3

Search NIH Clinical Center for Rheumatoid Arthritis, Systemic Juvenile

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: arthritis, juvenile

Genetic Tests for Rheumatoid Arthritis, Systemic Juvenile

Genetic tests related to Rheumatoid Arthritis, Systemic Juvenile:

id Genetic test Affiliating Genes
1 Rheumatoid Arthritis, Systemic Juvenile 29

Anatomical Context for Rheumatoid Arthritis, Systemic Juvenile

MalaCards organs/tissues related to Rheumatoid Arthritis, Systemic Juvenile:

39
Testes, Skin, Eye, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Rheumatoid Arthritis, Systemic Juvenile:

18
Joint

Publications for Rheumatoid Arthritis, Systemic Juvenile

Variations for Rheumatoid Arthritis, Systemic Juvenile

Expression for Rheumatoid Arthritis, Systemic Juvenile

Search GEO for disease gene expression data for Rheumatoid Arthritis, Systemic Juvenile.

Pathways for Rheumatoid Arthritis, Systemic Juvenile

Pathways related to Rheumatoid Arthritis, Systemic Juvenile according to GeneCards Suite gene sharing:

(show all 38)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 CRP HLA-DPB1 HLA-DQA1 HLA-DRB1 IL1A IL1R1
2
Show member pathways
13.31 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL1A IL1R1 IL1RN
3
Show member pathways
13.27 IL1A IL1R1 IL2RA IL6 LTA TNF
4
Show member pathways
12.77 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL1A IL2RA IL6
5
Show member pathways
12.76 IL2RA IL6 LTA TNF TNFRSF1B
6
Show member pathways
12.76 HLA-DPB1 HLA-DQA1 HLA-DRB1 HSPD1 IL1A IL2RA
7
Show member pathways
12.71 IL1A IL1R1 IL6 LTA TNF TNFRSF1B
8
Show member pathways
12.64 IL1A IL1R1 LTA TNF TNFRSF1B
9
Show member pathways
12.64 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL2RA TNF TNFRSF1B
10
Show member pathways
12.59 IL1A IL1R1 LTA TNF TNFRSF1B
11
Show member pathways
12.54 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL1A IL1R1 IL2RA
12
Show member pathways
12.26 IL1A IL1R1 IL6 MIF TNF
13
Show member pathways
12.25 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL1A TNF
14 12.17 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL1R1 IL2RA IL6
15 12.16 HSPD1 IL1A IL1RN IL6 TNF
16
Show member pathways
12.14 IL1A IL6 LTA TNF
17 12.05 HLA-DPB1 HLA-DQA1 HLA-DRB1 HSPD1 IL1A IL6
18 12 IL1A IL1R1 IL6 MIF TNF
19 11.98 IL1A IL6 TNF TNFRSF1B
20 11.95 IL6 LTA TNF TNFRSF1B
21 11.8 IL1R1 IL2RA LTA TNF
22
Show member pathways
11.78 LTA TNF TNFRSF1B
23 11.75 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL1A IL6 TNF
24 11.73 IL1A IL6 TNF
25 11.72 IL2RA IL6 LTA TNF
26
Show member pathways
11.66 IL1A IL6 MIF TNF
27 11.58 HLA-DPB1 HLA-DQA1 HLA-DRB1
28 11.57 HSPD1 IL6 TNF
29 11.56 IL1A IL1R1 LTA TNF TNFRSF1B
30
Show member pathways
11.52 LTA TNF TNFRSF1B
31 11.49 BGLAP IL1A IL6 TNF
32
Show member pathways
11.42 IL2RA TNF TNFRSF1B
33 11.35 IL1A IL6 TNF
34 11.27 HLA-DRB1 IL1A IL6 TNF
35 11.21 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL1A IL1R1 IL2RA
36 11.19 IL1A IL6 LTA TNF
37 11.12 IL1A IL1R1 IL1RN IL6 TNF TNFRSF1B
38 11.05 CRP IL6 TNF

GO Terms for Rheumatoid Arthritis, Systemic Juvenile

Cellular components related to Rheumatoid Arthritis, Systemic Juvenile according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.83 HLA-DRB1 IL2RA IL6 TNF
2 endosome membrane GO:0010008 9.8 HLA-DPB1 HLA-DQA1 HLA-DRB1 SLC11A1
3 trans-Golgi network membrane GO:0032588 9.69 HLA-DPB1 HLA-DQA1 HLA-DRB1
4 endocytic vesicle membrane GO:0030666 9.65 HLA-DPB1 HLA-DQA1 HLA-DRB1
5 ER to Golgi transport vesicle membrane GO:0012507 9.61 HLA-DPB1 HLA-DQA1 HLA-DRB1
6 transport vesicle membrane GO:0030658 9.58 HLA-DPB1 HLA-DQA1 HLA-DRB1
7 clathrin-coated endocytic vesicle membrane GO:0030669 9.54 HLA-DPB1 HLA-DQA1 HLA-DRB1
8 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.5 HLA-DPB1 HLA-DQA1 HLA-DRB1
9 cell surface GO:0009986 9.5 HLA-DPB1 HLA-DRB1 HSPD1 IL1R1 IL2RA MIF
10 MHC class II protein complex GO:0042613 9.33 HLA-DPB1 HLA-DQA1 HLA-DRB1
11 extracellular space GO:0005615 9.32 BGLAP CRP HSPD1 IL1A IL1RN IL6
12 plasma membrane GO:0005886 10.27 HLA-DPB1 HLA-DQA1 HLA-DRB1 HSPD1 IL1R1 IL1RN
13 extracellular region GO:0005576 10 BGLAP CRP IL1A IL1R1 IL1RN IL6

Biological processes related to Rheumatoid Arthritis, Systemic Juvenile according to GeneCards Suite gene sharing:

(show all 27)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 CRP IL1A IL6 SLC11A1 TNF
2 immune system process GO:0002376 9.97 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL2RA MIF S100A9
3 regulation of cell proliferation GO:0042127 9.92 IL6 MIF TNF TNFRSF1B
4 response to lipopolysaccharide GO:0032496 9.85 HSPD1 IL6 LTA SLC11A1 TNFRSF1B
5 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.8 HSPD1 S100A9 TNF
6 T cell costimulation GO:0031295 9.8 HLA-DPB1 HLA-DQA1 HLA-DRB1
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.79 IL6 MIF TNF
8 interferon-gamma-mediated signaling pathway GO:0060333 9.78 HLA-DPB1 HLA-DQA1 HLA-DRB1
9 positive regulation of T cell proliferation GO:0042102 9.77 HLA-DPB1 IL2RA IL6
10 humoral immune response GO:0006959 9.77 IL6 LTA TNF
11 antigen processing and presentation GO:0019882 9.76 HLA-DPB1 HLA-DQA1 HLA-DRB1
12 defense response to Gram-positive bacterium GO:0050830 9.73 CRP IL6 LTA TNF
13 positive regulation of cytokine secretion GO:0050715 9.69 IL1A MIF TNF
14 response to glucocorticoid GO:0051384 9.65 BGLAP HSPD1 IL1RN IL6 TNF
15 inflammatory response GO:0006954 9.65 CRP IL1A IL1RN IL2RA IL6 MIF
16 inflammatory response to antigenic stimulus GO:0002437 9.63 HLA-DRB1 IL2RA
17 positive regulation of interleukin-6 production GO:0032755 9.62 HSPD1 IL1A IL6 TNF
18 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.58 IL6 TNF
19 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.58 HLA-DPB1 HLA-DQA1 HLA-DRB1
20 positive regulation of neutrophil extravasation GO:2000391 9.56 IL1A IL1R1
21 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.55 LTA TNF
22 positive regulation of interferon-gamma production GO:0032729 9.55 HLA-DPB1 HSPD1 LTA SLC11A1 TNF
23 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.54 IL1RN IL6
24 negative regulation of lipid storage GO:0010888 9.54 CRP IL6 TNF
25 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.52 MIF TNF
26 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.48 LTA TNF
27 immune response GO:0006955 9.4 HLA-DPB1 HLA-DQA1 HLA-DRB1 IL1A IL1R1 IL1RN

Molecular functions related to Rheumatoid Arthritis, Systemic Juvenile according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 9.16 HLA-DQA1 HLA-DRB1
2 peptide antigen binding GO:0042605 9.13 HLA-DPB1 HLA-DQA1 HLA-DRB1
3 cytokine activity GO:0005125 9.1 IL1A IL1RN IL6 LTA MIF TNF

Sources for Rheumatoid Arthritis, Systemic Juvenile

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....